注射用脑蛋白水解物(Ⅱ)对急性脑梗死患者的临床疗效观察  

Effect of cerebroprotein hydrolysate for injection(Ⅱ) on the clinical prognosis of patients with acute cerebral infarction

作　　者：王欣蕾 张雪 岳赞[1] 迟丰田 台立稳[1] 贺丹[1] Wang Xinlei;Zhang Xue;Yue Zan;Chi Fengtian;Tai Liwen;He Dan(Department of Neurology,the Second Hospital of Hebei Medical University,Shijiazhuang 050000,China)

机构地区：[1]河北医科大学第二医院神经内科,石家庄050000

出　　处：《脑与神经疾病杂志》2018年第9期534-538,共5页Journal of Brain and Nervous Diseases

摘　　要：目的研究注射用脑蛋白水解物(Ⅱ)对急性脑梗死(ACI)患者的神经功能缺损及认知功能的影响。方法选取2017年9月至2018年2月河北医科大学第二医院神经内科收治的ACI患者(发病≤3d)患者100例,随机分为治疗组和对照组,各50例。对照组予以ACI患者常规治疗,治疗组在对照组基础上加用注射用脑蛋白水解物(Ⅱ),连续使用(14±3)d,对比两组患者美国国立卫生研究院卒中量表(NIHSS)、简易智力状态检查量表(MMSE)、蒙特利尔认知评估量表(MOCA)、改良Rankin量表(MRS)评分。结果对照组中1例患者出院后随访中因心肌梗死死亡,予以停止随访观察。治疗前,治疗组及对照组的NIHSS、MMSE、MOCA、MRS评分比较差异无统计学意义(P>0.05)。治疗后,两组各自组内比较第7天、14天、30天两组NIHSS、MMSE、MOCA、MRS评分较治疗前均有改善(P<0.05),两组MRS评分组间比较改善值差异无统计学意义(P>0.05);治疗组NIHSS评分、MMSE评分、MOCA评分组间比较总改善值显著高于对照组(P<0.05)。结论注射用脑蛋白水解物(Ⅱ)能明显改善ACI患者神经功能缺损和认知功能障碍,有临床应用价值。Objective To study the effect of cerebroprotein hydrolysate for injection(II)on neural function defect and cognitive function in patients with acute cerebral infarction(ACI).Method 100 patients with ACI hospitalized in Department of Neurology,Second Hospital of Hebei Medical University,from October 2017 to January 2018 were randomly divided into treatment group and control group,50 cases in each group.The control group was given ACI routine treatment.The on the basis of the control group,and continuously used for(14±3)days.The scores of NIHSS,MMSE,MOCA and MRS were compared between the two treatment group was added cerebroprotein hydrolysate for injection(II)groups.Results In the control group,1 patient died of myocardial infarction after discharge,and the follow-up observation was stopped.Before treatment,NIHSS,MMSE,MOCA,MRS score had no significant difference between the treatment group and the control group;after 7 days,14 days,30 days,NIHSS score,MMSE score,MOCA score improved significantly higher in the treatment group than in the control group(P<0.05),while MRS score was no significant difference between the treatment group and the control group(P>0.05).Conclusion Cerebroprotein hydrolysate for Injection(II)could obviously improve the neural function defect and cognitive impairment in ACI patients,and it is worthy of clinical application.

关 键 词：注射用脑蛋白水解物(II) 急性脑梗死 神经功能缺损 认知障碍 

分 类 号：R743.32[医药卫生—神经病学与精神病学]